Pharmaceutical Law Group assists businesses and funds in corporate agreements, acquisition, sales, and other transactions involving FDA-regulated products, entities, and activities.
FDA Regulatory Transactional Matters
As a registered patent attorney and non-practicing physician, Gregory Glover regularly advises life sciences companies, investors, and trade associations on the complex interactions of Food and Drug Administration regulations, technology licensing, and intellectual property law.
With extensive expertise in regulatory matters involving drug products, biologics, diagnostics, and medical devices, Dr. Glover provides valuable insight into a variety of pharmaceutical and biotechnology transactional matters, including:
- Corporate Partnering
- Divestitures
- IPOs and Financing
- Joint Ventures
- Licensing Arrangements
- Manufacturing, Supply, and Distribution Agreements
- Mergers and Acquisitions
- Private Transactions
Greg provides counsel and analysis for life sciences companies, institutions, and research organizations on arrangements involved in discovery, development, manufacture, and marketing.
IP-Related Transactions
As a registered patent attorney, Dr. Glover’s expertise at the intersection of FDA regulation and intellectual property lends valuable IP transaction advice in corporate matters involving drug, biologic, and medical device products to provide practical, creative, and rapid solutions to clients’ legal challenges.
Our investigations include a review of market protections, FDA citizen petitions, patent strengths, USPTO proceedings, potential and ongoing patent litigation (including foreign litigation), and impacts on profits, royalty income, and market exclusivity.
This expertise provides clients with a complete view of the benefits and risks of an IP transaction involving pharmaceutical, biologic, and medical device assets.
Regulatory IP Expertise
Pharmaceutical Law Group helps drug sponsors, manufacturers, pharmaceutical and biotech companies, and investors apply unique and insightful strategies across the product life cycle to ensure efficient, competitive, and profitable market entry.
With decades of experience handling matters at the intersection of FDA regulation and intellectual property, we help life sciences investors, companies, and other clients uncover risks and identify opportunities in life cycle management, product development, and regulatory incentives.
Gregory Glover, MD JD, is nationally renowned authority on Regulatory IP matters, providing in-depth regulatory knowledge and expertise on the complex interactions between intellectual property, FDA regulation, and market dynamics.
To Connect with Gregory Glover and Pharmaceutical Law Group
Contact Pharmaceutical Law Group at 202.589.1780 or by EMAIL